Immutep Limited American Depositary Shares (IMMP)
Stock · NASDAQ · Health Care
$3.2as of 10/16/2026
Price chart
Active signals
IMMP Signal Track Record
How signals performed across all stocks →What IMMP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -3.3% | 39% | September 18, 2026 |
| Bollinger Band Breakout | 23 | -3.5% | 35% | September 28, 2026 |
| Bollinger Band Breakdown | 21 | +1.8% | 52% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +0.5% | 54% | December 4, 2025 |
| Any 20-session window (baseline) | -2.0% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMMP
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.immutep.com/
Fundamentals
- 1-day range
- $3.06$3.31
- Market cap
- $55.21M
- P/E (trailing)
- —
- P/E (forward)
- -0.62
- EPS (trailing)
- $-0.05
- Dividend yield
- —
- Beta
- 2.10
- Avg. volume
- 15.7K
- Dividend pay date
- December 28, 2016
Forecasts
1 analyst ratings
Immutep Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- IMMPImmutep Limited American Depositary Shares$3.2▼ 0.31%Market cap $55.21MP/E —$0.022$0.47
- INCRIntercure Ltd. Ordinary Shares$4.57▼ 1.72%Market cap $54.80MP/E —$253.3$2,740
- SDEVStablecoin Development Corporation Common Stock$0.88▼ 13.73%Market cap $52.64MP/E 0.16$0.7809$99.75
- CPHIChina Pharma Holdings Inc. Common Stock$0.71▼ 2.74%Market cap $52.06MP/E —$0.3818$19.19
- RNXTRenovoRx Inc. Common Stock$1.14▼ 4.20%Market cap $51.86MP/E —$0.7006$2.59
- SCYXSCYNEXIS Inc. Common Stock$3.67▼ 6.14%Market cap $51.64MP/E —$3.53$9.12
- DWTXDogwood Therapeutics Inc. Common Stock$1.22▼ 2.40%Market cap $58.85MP/E —$1.24$7.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMMP Immutep Limited American Depositary Shares | $55.21M | — | $3.2 | ▼ 0.31% | $0.022$0.47 |
| INCR Intercure Ltd. Ordinary Shares | $54.80M | — | $4.57 | ▼ 1.72% | $253.3$2,740 |
| SDEV Stablecoin Development Corporation Common Stock | $52.64M | 0.16 | $0.88 | ▼ 13.73% | $0.7809$99.75 |
| CPHI China Pharma Holdings Inc. Common Stock | $52.06M | — | $0.71 | ▼ 2.74% | $0.3818$19.19 |
| RNXT RenovoRx Inc. Common Stock | $51.86M | — | $1.14 | ▼ 4.20% | $0.7006$2.59 |
| SCYX SCYNEXIS Inc. Common Stock | $51.64M | — | $3.67 | ▼ 6.14% | $3.53$9.12 |
| DWTX Dogwood Therapeutics Inc. Common Stock | $58.85M | — | $1.22 | ▼ 2.40% | $1.24$7.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaborationbenzinga · 10/14/2026
- Immutep Receives ~A$0.86 Million R&D Tax IncentiveYahoo · 9/30/2026
- Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive ProgramBenzinga · 9/30/2026
- Change to American Depositary Share RatioYahoo · 9/21/2026
- Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28Benzinga · 9/21/2026
- What's going on in today's after hours sessionChartMill · 9/14/2026
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)Yahoo · 9/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 2.63M
- Total value held
- $907.6K
- Institutional holders
- 27
- Unknown810.9K
- Unknown748.8K
- Unknown449.6K
- Unknown124.8K
- Unknown94.2K
- Unknown73.8K
- Unknown53.6K
- Unknown41.4K
- Unknown34.0K
- Unknown30.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Immutep Receives A$856,669 R&D Tax Rebate
Immutep Limited has received a cash rebate of A$856,669 from the Australian federal government’s R&D Tax Incentive Program. The rebate supports the company’s research and development activities and provides additional liquidity. This inflow may help fund future projects and strengthen the balance sheet. The news reflects ongoing government support for biotech innovation in Australia.
Immutep Receives A$856,669 R&D Tax Rebate. Immutep Limited has received a cash rebate of A$856,669 from the Australian federal government’s R&D Tax Incentive Program. The rebate supports the company’s research and development activities and provides additional liquidity. This inflow may help fund future projects and strengthen the balance sheet. The news reflects ongoing government support for biotech innovation in Australia.